DKDarya S. Kaskaeva

Darya S. Kaskaeva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Darya S. Kaskaeva has a total of 667 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Incidence of chronic obstructive pulmonary disease in the newly diagnosed microalbuminuria population: retrospective analysis of the AURA registry database

    by G. P. Arutyunov, E. I. Tarlovskaya, M. A. Trubnikova, A. G. Arutyunov, D. S. Polyakov, M. M. Batyushin, S. Sh. Akhmedkhanov, I. G. Bakulin, I. A. Bodrievskaya, I. A. Viktorova, et al.

    Aim. To analyze the phenotypes of patients at highest risk for albuminuria (AU) in a population of patients without diabetes and to estimate its prevalence in the identified phenotypes. Material and methods. A total of 4580 patients over 40 years of age without type 1 or 2 diabetes, who had not previously been diagnosed with chronic kidney disease, were included in a real-world practice registry of AU detection in patients with previously undiagnosed CKD — AURA. The registry design did not include patient follow-up. AU was determined using sensitive micral-test strips, with an AU cutoff of 20 mg/L. Results. AU ≥20 mg/L was present in 64,9% of cases. According to univariate analysis, patients with AU compared with those without it were more likely to have the following risk factors: hypertension (79% vs 71,5%), male sex (44,2% vs 38,6%), smoking (31% vs 25,2%), metabolic syndrome (32% vs 23,4%), as well as diseases such as coronary artery disease (35,5% vs 29,7%), heart failure (41,5% vs 35%), atrial fibrillation (17,3% vs 12,5%), prediabetes (14,7% vs 8,9%), chronic obstructive pulmonary disease (COPD) (7,67% vs 3,76%), chronic cystitis (5,35% vs 3,49%). A multivariate model revealed that age (with each 1-year increase in age, the risk of AU increased by 2%, p-value Conclusion. A multivariate analysis of AURA registry data confirmed that AU is independently associated with conditions such as post-infarction cardiosclerosis, atrial fibrillation, prediabetes, metabolic syndrome, chronic cystitis, and COPD. Of particular interest is the study and follow-up of patients with COPD, in whom AU was found in 78,9%.

  • Эпоха пероральных антикоагулянтов и экстренная хирургия

    by Наталья Юрьевна Шимохина, Марина Михайловна Петрова, Вадим Алексеевич Кашинцев, Карина Витальевна Курочкина, Дарья Сергеевна Каскаева, Татьяна Григорьевна Захарова, Игорь Витальевич Барсуков, Ксения Юрьевна Демченко

    Введение прямых пероральных антикоагулянтов в клиническую практику, наряду с сохранением применения антагонистов витамина К, привело к увеличению числа пациентов, поступающих на экстренные хирургические вмешательства на фоне антикоагулянтной лекарственной терапии. В отличие от плановой хирургии, ургентные ситуации требуют мгновенного принятия решений в условиях временного дефицита и конкурирующих рисков тромбоза и кровотечения. В представленной обзорной статье рассматриваются современные клинические рекомендации и ключевые исследования, посвященные периоперационному ведению данной категории больных. Особое внимание уделяется алгоритмизации подхода, основанного на стратификации срочности вмешательства, оценке геморрагического риска процедуры, фармакокинетических параметрах (время последнего приема, функция почек) и селективном применении лекарственных средств реверсии (андексанет альфа, четырехфакторный концентрат протромбинового комплекса). Анализируются данные по ведению пациентов с переломами проксимального отдела бедра, демонстрирующие возможность и безопасность раннего хирургического лечения при условии протоколизированного подхода. Освещаются нерешенные вопросы, включая отсутствие унифицированных пороговых уровней прямых пероральных антикоагулянтов для принятия решений о реверсии и неопределенность в сроках возобновления антикоагуляции после высокорисковых вмешательств. Делается вывод о необходимости перехода от эмпирических задержек операций к формализованным внутрибольничным протоколам, интегрирующим усилия хирурга, анестезиолога и смежных специалистов для минимизации осложнений и улучшения прогноза.

  • PATHOPHYSIOLOGY OF MYOCARDIAL INFARCTION: HISTORICAL ESSAYS AND NEW HORIZONS

    by Marina M. Petrova, Natalia Yu. Shimokhina, Alexander A. Evsyukov, Natalia A. Schneider, Daria S. Kaskaeva, Sanjarkhon H. Kudratov

    Highlights In the analytical review, the main pathophysiological mechanisms of myocardial infarction development are presented, including complex molecular processes that lead to ischemia and necrosis of the heart muscle. Historically, understanding of this condition has come a long way from its first descriptions to modern diagnostic and treatment methods, which have significantly improved the prognosis for patients with MI. Understanding the history and pathophysiology of myocardial infarction is key to medical practice, research, and patient education. This knowledge contributes to improved diagnosis, treatment, and prevention, which ultimately leads to improved quality of life for patients and a reduced burden of cardiovascular disease at the societal level. Abstract Understanding the historical aspects and pathophysiology of myocardial infarction is important for both medical professionals and patients. Knowledge of the mechanisms of myocardial infarction development allows physicians to more accurately assess the patient’s condition and choose optimal treatment methods, including drug therapy and interventional procedures. An analysis of scientific literature and articles published over the past decade was conducted using the resources of the PubMed and eLibrary search engines using the following keywords: atherosclerosis, history of myocardial infarction, pathophysiology of myocardial infarction, ischemic heart disease, pathogenesis of atherothrombosis, endothelium, inflammation. In the selection, preference was given to systematic reviews and meta-analyses as sources with the highest level of evidence, as well as randomized controlled trials (RCTs), large cohort studies and authoritative clinical guidelines.


  • Pathophysiology of vascular cognitive disorders associated with myocardial infarction

    by A. A. Evsyukov, M. M. Petrova, N. A. Shnayder, N. Yu. Shimokhina, D. S. Kaskaeva, A. R. Leyman, S. N. Azimova, A. M. Bekuzarova, S. S. Stepanenko

    According to the World Health Organization, there is an anticipated increase in the number of patients suffering from dementia by 2030. Unfortunately, the initial symptoms noticeable to patients and their surroundings tend to appear relatively late after the onset of the disease, which is a poor prognostic factor. There are numerous etiological factors contributing to the development of cognitive impairments. Vascular dementia accounts for the second most common type of dementia among disease cases and will be discussed in this article. It is important to note that lipid metabolism disorders affect approximately 58.4% of the Russian population, representing one of the main risk factors for myocardial infarction, which is directly associated with the development of vascular cognitive disorders (VCD). According to the studies referenced in this review, it was found that patients who have experienced a myocardial infarction show an increased risk of developing cognitive disorders related to pathological changes such as neuroinflammation and reduced density of dendritic cells. Additionally, it was determined that apoptosis and alterations in “Alzheimer’s-associated” proteins across different brain regions during myocardial conditions contribute to the development of vascular cognitive impairment. The pathophysiological link between myocardial infarction and VCD is mediated by vascular dysregulation, impaired cerebral perfusion, and factors such as oxidative stress, inflammation, neurovascular dysfunction, atherosclerosis, and reperfusion injury, leading to microinfarctions, hypoperfusion, and cognitive impairment. An increased risk of developing VCD is observed in patients following coronary revascularization, necessitating special attention to their cognitive status in the post-primary period.


  • Open Access

    Epidemiology of acute myocardial infarction in the Russian Federation and abroad from 2017 to 2024

    by Marina M. Petrova, Alena R. Anokhina, Sergey A. Ustyugov, Darya S. Kaskaeva, Aleksandr A. Evsyukov, Natalia A. Schneider, Устюгов Сергей Александрович, Шнайдер Наталья Алексеевна

    Acute myocardial infarction (AMI) remains a major public health concern worldwide. The aim of this narrative review was to identify and summarize the results of epidemiological studies on AMI incidence in Russia and abroad. Russian and international publications were searched in the databases eLibrary, PubMed, and Google Scholar. The search covered the previous 5 years. The analysis showed that the incidence rate of AMI in the Russian population during the study period remained high, reaching 140.8 cases per 100,000 population by 2022. This rate was lower compared with some CIS countries (Belarus, 174.5 cases) and European countries (Sweden, 288.0 cases; United Kingdom, 288.0 cases; France, 180.2 cases; Hungary, 177.5 cases; Spain, 169.0 cases; Cyprus, 160.0 cases), as well as New Zealand (536.0 cases), the United States (439.9 cases), Japan (389.7 cases), Australia (352.0 cases), Iran (343.0 cases), China (231.6 cases), and Tanzania (172.0 cases). These findings indicate that the incidence of AMI remains high both in Russia and globally, with an upward trend among middle-aged individuals. This highlights the need for future multicenter epidemiological studies of AMI incidence in Russia, particularly among adults aged 45–59 years, to support the development of new diagnostic and therapeutic strategies.


  • Open Access

    The pattern of circulating micrornas in acute myocardial infarction

    by М. М. Petrova, N. A. Shnayder, D. V. Dmitrenko, A. V. Petrov, D. S. Kaskaevа, A. A. Evsyukov

    Acute myocardial infarction (AMI) is a potential life-threatening complication of coronary heart disease and occupies a leading place in the mortality structure of the population. In recent years, methods of early diagnosis of AMI and comorbid conditions have been improved, which can play an important role in a personalized approach to therapy and prediction of outcomes and complications. The problem of developing and introducing new sensitive and specific biochemical and molecular biomarkers of AMI into real clinical practice is of great interest to Russian and foreign researchers.   The purpose of this thematic review is to search, summarize and systematize the results of fundamental and clinical studies of the role of microRNAs as sensitive and specific molecular biomarkers of AMI. The authors conducted a search for publications in the databases PubMed, Web of Science, Scopus, Cochrane Library, Springer, ClinicalKey, Oxford Press, e-Library using keywords and their combinations. Publications from 2009–2024, including original clinical studies of AMI, were analyzed. As a result of this review, it was shown that circulating miR-1, miR-133a, and miR-208a can be considered promising molecular biomarkers of AMI. The presented brief review indicates that the early diagnosis of AMI has prospects for development due to the development and introduction into real clinical practice of new laboratory tests, including the study of the level of circulating microRNAs in the blood from the first hours of the development of acute coronary syndrome.


  • Open Access

    PATTERN OF CIRCULATING MICRORNAS IN VASCULAR COGNITIVE DISORDERS

    by Марина Михайловна Петрова, Natalia A. Shnayder, Артем Владимирович Петров, Дарья Сергеевна Каскаева, Вера Васильевна Трефилова, Регина Фаритовна Насырова, Наталья Алексеевна Шнайдер

    Highlights Studying circulating microRNAs in vascular cognitive disorders significantly contributes towards understanding the molecular mechanisms of development and progression of these disorders. Studying microRNAs allows us to identify new biomarkers that can be used to diagnose, predict the course of the disease and determine the effectiveness of treatment. AbstractVascular cognitive disorders (VCD) are one of the most common forms of non-psychotic mental disorders with a variable phenotype and rate of progression, transformation into vascular dementia. VCD develops due to existing cardiovascular diseases (CVD), which highlights the importance of an interdisciplinary approach to diagnosis and treatment of these diseases. The study of new mechanisms of the development of VCD can help in finding the key to the development of innovative diagnostic methods and personalized treatment approaches. In recent years, the role of non-coding ribonucleic acids (RNA) has been actively studied, while the greatest interest of researchers and clinicians is focused on studying the role of microRNAs (miR). The aim of this review was to search, generalize and systematize preclinical and clinical studies on the role of circulating miR as molecular biomarkers of the development and progression of VCD. The authors searched for publications in the following databases PubMed, Springer, Web of Science, ClinicalKey, Scopus, Oxford Press, Cochrane, e-Library using keywords and their combinations. The publications published in 2013–2023 were analyzed, including original clinical studies of VCD and vascular dementia. The findings of this review show that miR-409-3p, miR-502-3p, miR-486-5p and miR-451a can be considered as promising molecular biomarkers of VCD. However, the role of other microRNAs is debatable and needs further study. In the future, it will be possible to consider previously studied circulating microRNAs with high specificity and sensitivity to VCD and vascular dementia as prognostic molecular biomarkers (predictors) of the risk of their development and severity in patients with CVD.Based on the analysis of the results of preclinical and clinical studies, the authors present the most sensitive and specific microRNAs associated with the development and rapid progression of VCD in people with cerebrovascular and cardiovascular diseases. Moreover, microRNAs have been demonstrated to facilitate the differential diagnosis of VCD and cognitive disorders in Alzheimer's disease and Parkinson's disease.

  • Open Access

    Analysis of data from the Russian AURA registry (real-world data registry on AlbUminuRia detection rate among patients with previously undiAgnosed chronic kidney disease)

    by M. M. Batyushin, M. A. Trubnikova, G. P. Arutyunov, E. I. Tarlovskaya, A. G. Arutyunov, D. S. Polyakov, S. Sh. Akhmedkhanov, I. G. Bakulin, I. A. Bodrievskaya, I. A. Viktorova, et al.

    Aim. To present data from the AURA Registry (real-world data registry on AlbUminuRia detection rate among patients with previously undiAgnosed chronic kidney disease). It is important to perform population studies both to study the occurrence of markers (albuminuria (AU), decreased glomerular filtration rate (GFR)) and the prevalence of chronic kidney disease (CKD), which will provide information on the actual detection rate of CKD and the related markers in territories included in the registry of research centers.Material and methods. The article presents the first data from the AURA registry. Recruitment was carried out from March 6, 2023 to January 23, 2024. Thirty-four research centers in various federal districts of the Russian Federation and 104 doctors took part in the recruitment. We included 4580 subjects over the age of 40 years who had no previously established diagnosis of CKD and did not have type 1 or type 2 diabetes. During recruitment, the researchers were guided by the AURA study protocol (Version 1.7/12-26-2022).Results. AU more than 20 mg/g was detected in 64,9% of cases. At the same time, AU is more common at GFR values that may correspond to stage 3A of CKD. The rarer occurrence of AU in those examined with GFR >60 ml/min/1,73 m2 may be explained by less severe renal damage at this CKD stage. The incidence of AU was significantly higher in men, older people, smokers, people with metabolic syndrome, hypertension (HTN), prediabetes and overweight. The occurrence of AU also increased as HTN grade increased. AU detection rate was associated with hypertriglyceridemia, a high blood level of C-reactive protein, which is an integrative marker of inflammation that negatively affects cardiovascular risk.Conclusion. The presented first data from the AURA registry demonstrated the high AU prevalence in people over 40 years of age. A high incidence of AU was typical for patients with HTN, coronary artery disease, atrial fibrillation, heart failure, and prediabetes. An association has been demonstrated between the high incidence of AU and male sex, age, overweight, hyperuricemia, dyslipidemia, and a number of other cardiovascular risk factors.

  • Open Access

    2023 All-Russian screening for hypertension: results

    by О. П. Ротарь, I. N. Ilyanova, M. A. Boyarinova, E. V. Moguchaya, K. M. Tolkunova, V. A. Dyachkov, O. A. Rubanenko, A. O. Rubanenko, O. E. Gaberman, E. Yu. Gubareva, et al.

    Aim. To assess awareness of blood pressure (BP) level, adherence to therapy and achievement of target BP in residents of Russian regions as part of the 2023 hypertension (HTN) screening campaign.Material and methods. During May 2023, 4613 participants from 23 cities of Russia took part in the screening. Participation was voluntary without restrictions on sex. All patients aged over 18 years. During screening, BP and pulse were measured three times using automatic or mechanical BP monitors, and a questionnaire about behavioral risk factors, concomitant diseases and therapy was filled out. HTN was diagnosed with systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg and/or taking antihypertensive therapy (AHT).Results. The analysis included data from 4585 respondents aged 18 to 95 years with an average age of 45 [28;59] years, of which 1729 were men (37,7%). The proportion of hypertensive patients was 49,6%. Among them, 62,8% took AHT and achieved target BP in 76,6% and 45,7% with the target BP criterion Conclusion. The data obtained indicate, on the one hand, a continuing insufficient level of awareness about high BP and the use of antihypertensive drugs among the population, but there is a tendency to improve the effectiveness of the treatment of hypertension, including the use of fixed-dose combinations of antihypertensive drugs.


  • Open Access

    FREQUENCY OF ANXIETY DISORDERS IN PATIENTS WITH ARTERIAL HYPERTENSION AND COMORBID DISEASES

    by Elena A. Pronina, Natalya Yu. Shimokhina, Darya S. Kaskaeva, Lyudmila K. Danilova, Olga V. Tutinina, Svetlana Yu. Shtarik, Мarina М. Petrova

    Background. Anxiety is more common in patients with hypertension. The comorbid presence anxiety disorders and arterial hypertension complicates medical treatment, may change the severity and/or progression of disease. Objective. To study the influence of comorbid diseases on the development of anxiety disorders in patients with hypertension in outpatient practice. Methods. This observational cohort study employed the State‐Trait Anxiety Inventory (STAI, Spielberger anxiety scale) to assess symptoms of anxiety in several groups with hypertension. The study cohort included 360 patients with isolated hypertension, 172 patients with hypertension in combination with obesity and 72 patients with comorbid hypertension and type 2 diabetes mellitus (DM) Results. A high incidence of anxiety disorders was found in patients with hypertension 98.06% regardless of the presence of obesity 97.09% and type 2 diabetes 98.18%. The incidence and severity of trait anxiety in the examined patients was the lowest in the group of patients with hypertension in combination with obesity 59.65%, compared with patients with isolated hypertension 68.61% p =0.042045 and the group of hypertension in combination with type 2 diabetes 78.18% p=0.012662. According to the severity of the combination of hypertension with obesity, patients with a low 40.35% and an average 41.52% indicator of trait anxiety prevailed, in patients with hypertension in combination with type 2 diabetes, an average 52.73% and a high 25.45% level of anxiety were more often observed (p<0.5). The presence of type 2 diabetes increases the frequency and severity of state anxiety in patients with hypertension. Thus, patients with hypertension in combination with type 2 diabetes were more likely to have a high (50.91%) level of state anxiety, while patients with isolated hypertension were more likely to have low (5.56%) and medium (70.35%) levels of anxiety disorders.